UNSPSC 51131724: Midazogrel

This classification denotes an antiplatelet agent with the molecular formula C18H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04HCK0SD2O, chemically known as 1h-imidazole, 1-(3-(phenylmethoxy)-1-octenyl)-, (e)- but generally known as midazogrel, which bears US NIH Compound Identifier 6436121. European Medicines Agency schedules Midazogrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08949MIG.

UNSPSC 51131724 Midazogrel is a Commodity code that appears to have minimal alignment with actual state and local procurement activity. The single recent opportunity tagged under this code—Sourcewell RFP #061626, posted May 12, 2026, due June 16, 2026—solicits law enforcement equipment on behalf of a cooperative purchasing vehicle serving multiple counties, school districts, and public entities across Washington state and nationwide. The solicitation itself contains no reference to Midazogrel, a pharmaceutical antiplatelet agent, and the scope of work (law enforcement equipment procurement) falls entirely outside the pharmaceutical or medical-supply realm that the code nominally describes. This mismatch suggests either a tagging error in the source data or that the code is not currently being used to classify actual state and local procurement for the product it names.

The Sourcewell cooperative procurement represents activity across Franklin County, Grant County, Grays Harbor County, Chelan County, and Yakima County in Washington state, with participation available to thousands of public entities throughout the United States and Canada, but the substantive procurement—law enforcement equipment—does not reflect demand for Midazogrel or similar pharmaceutical products in the state and local market. No other recent opportunities appear in the source data. State and local procurement activity under this code does not currently support a pursuit strategy; vendors with law enforcement equipment offerings may find value in the Sourcewell RFP structure, but pharmaceutical suppliers should not rely on this code to identify relevant state and local market segments.